Percheron Therapeutics Narrows Half-Year Loss but Sees Net Assets Per Share Fall

An update from Percheron Therapeutics ( (AU:PER) ) is now available.

Percheron Therapeutics Limited reported a significantly reduced half-year loss for the period ended 31 December 2025, with net loss after tax falling 64% to $3.1 million from $8.5 million a year earlier. The company held cash reserves of $4.46 million at period end, indicating a moderated cash burn but continued dependence on external funding to support its therapeutic development activities.

Net tangible assets per share declined to 0.66 cents from 1.41 cents, underscoring ongoing balance sheet dilution and asset erosion typical of pre-revenue biotech firms. No dividends were paid or declared for the current or prior corresponding periods, consistent with the company’s focus on reinvestment in research and development rather than shareholder cash returns.

The most recent analyst rating on (AU:PER) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on Percheron Therapeutics stock, see the AU:PER Stock Forecast page.

More about Percheron Therapeutics

Percheron Therapeutics Limited is a healthcare company operating in the therapeutics sector, focused on developing medical treatments and related technologies. The company is publicly listed and reports periodic financial results to its shareholders, reflecting its position as an early-stage or development-focused biotech enterprise that is not yet generating profits or paying dividends.

Average Trading Volume: 6,815,869

Technical Sentiment Signal: Sell

Current Market Cap: A$7.61M

See more data about PER stock on TipRanks’ Stock Analysis page.